Q&A: Using liquid biopsies 
to build CDx in pancreatic cancer with Actuate Therapeutics

Dr. Andrew Mazar of Actuate Therapeutics shares his perspective on liquid biopsy as a tool for CDx and drug development in pancreatic cancer.

Jun 28, 2023
Life Sciences
Pancreatic
Liquid Biopsy
Article
Michael YasiejkoGeneral Manager and Executive Vice President, Tempus
Andrew Mazar, PhDChief Operating Officer, Actuate

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Unable to determine image content.

Integrating multimodal real-world data at trial design: a framework for improving oncology trials

2026-10-06
Life Sciences
RWD
Clinical Trials
White abstract folded triangle shape, pointing right, on a black background.Video
Abstract rings of light on a pale gradient beneath the words “With Tempus, you can move faster.”

The Tempus Data Advantage

2026-09-30
Life Sciences
Pan-Cancer
RWD
White abstract folded triangle shape, pointing right, on a black background.Video
A survival analysis chart beneath the words “embrace the modalities that matter.”

The Next Era of Precision Medicine

2026-09-29
Life Sciences